GCIA
VERV

Gabelli & Co Investment Advisers’s Verve Therapeutics VERV Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-302,400
Closed -$3.4M – 328
2025
Q2 		$3.4M Buy
+302,400
New +$1.72M 0.52% 46

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Gabelli & Co Investment Advisers's VERV Position: Q3 2025 in Review

Gabelli & Co Investment Advisers sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 302,400 shares — an estimated $3.4M sold.

Gabelli & Co Investment Advisers first reported a position in VERV in Q2 2025 and held it in 1 quarter. The position peaked at $3.4M in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Gabelli & Co Investment Advisers reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 302,400 Verve Therapeutics shares in Q3 2025, an estimated $3.4M.
  • Gabelli & Co Investment Advisers first reported a position in Verve Therapeutics in Q2 2025 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Verve Therapeutics position peaked at $3.4M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Gabelli & Co Investment Advisers's 13F filing for Q3 2025, filed 12 Nov 2025.